Press Releases

afabicin (Debio 1450) afabicin (Debio 1450) ABSSSI afabicin (Debio 1450) Bone & joint infections CARB-X Clinical Trials CPP cyclosporin A Debio 0123 Debio 025 Debio 0507 Debio 0513 Debio 0517 Debio 0614 (istaroxime) Debio 0615 Debio 0617 Debio 0719 Debio 0824 Debio 0826 Debio 0827 Debio 0928 Debio 0929 Debio 0930 Debio 0931 Debio 0932 NSCLS Debio 0932 RCC Debio 1036 Debio 1124 Debio 1141 Debio 1142 Debio 1143 Debio 1143 Head & neck cancer Debio 1143 NSCLC Debio 1143 Ovarian cancer Debio 1144 Debio 1347 Debio 1348 Debio 1449 Debio 1453 Debio 1454 Debio 1460 Debio 1561 Debio 1562 Debio 8206 SC Debio 8609 Sanvar Debio 9902 - ZT-1 Debiopharm Life Sciences Award Debiovision EPFL EPI-hNE4 FibroTrap H3 Pharma Huperzine-A JCA-Mauvernay Award Moapar Muscular Dystrophy naratuximab emtansine (Debio 1562) Oncology Chair Oxaliplatin PLGA Spinomix Tremelimumab Triptorelin

May 14, 2002

Debiopharm S.A. reports study revealing that EPI-HNE4 offers protection against acute lung injury

March 24, 2002

Debiopharm SA a acquis un nouveau bâtiment à Lausanne et projette de déménager vers la fin 2004

March 17, 2002

H3 Pharma Licenses in Phase II Product for Stomach Cancer and Acquires Stake in a Human mAb Discovery Company Specializing…

July 5, 2001

Swiss drug developer Debiopharm announces FDA approval of Trelstar TM LA for therapeutic use

April 14, 2001

Debiopharm and Aurigene sign agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology…

February 13, 2001

Dyax Corp. and Debiopharm S.A. report initiation of phase II clinical trial with EPI-HNE-4 for cystic fibrosis

January 10, 2001

Swiss drug developer Debiopharm S.A. achieves another success in the development of molecules for theraeutic use